img

TCT Conference 2017

Here you will find the highlights of the TCT Conference 2017, held on October 29-31 and November 1-2 in the city of Denver, Colorado (USA).

TCT 2017 | Resultados finales del dispositivo Watchman

TCT 2017 | PREVAIL: Final Outcomes of the Watchman Device
Courtesy of SBHCI. The final 5-year outcomes of the PROTECT AF and PREVAIL studies (which assessed the left atrial appendage closure device Watchman) continues to show similar stroke ...

TCT 2017 | Estudio TRI-REPAIR y estudio FORMA: nuevos dispositivos para la “válvula olvidada”

TCT 2017 | The TRI-REPAIR and the FORMA Trials: New Devices for the “Forgotten Valve”
Courtesy of SBHCI. Two new transcatheter treatments for severe or massive functional tricuspid regurgitation have showed good results at 30 days, according to their feasibility ...

TCT 2017 | INTREPID: reemplazo mitral con prótesis autoexpandible

TCT 2017 | INTREPID: Mitral Replacement with a Self-Expanding Device
Courtesy of the SBHCI. Intrepid is a 43-, 46-, and 50-mm nitinol self-expanding valve with bovine pericardial leaflets that is placed using a transapical delivery system with a 35-Fr ...

TCT 2017 | MAVERIC: resultados a 6 meses del reemplazo mitral por catéter

TCT 2017 | MAVERIC: Results 6 Months After Transcatheter Mitral Valve Replacement
 Courtesy of the SBHCI. This seems to be the year for transcatheter mitral valve devices , and the ARTO system tested in this study looks promising for the treatment of patients ...

FAME 2 a 3 años: mejores resultados con angioplastia y a un costo similar que el tratamiento médico

TCT 2017 | FAME 2 at 3 Years: Better Results with Angioplasty and at a Cost Similar to Medical Treatment
Courtesy of SBHCI. Angioplasty in patients with chronic stable angina and functionally significant lesions improves clinical outcomes and quality of life over the long term, as compared ...

TCT 2017 | ORBITA: el efecto placebo de la angioplastia

TCT 2017 | ORBITA: The Placebo Effect of Angioplasty
Courtesy of the SBHCI. Chronic stable angina and severe coronary lesion patients who undergo angioplasty in a single vessel show no better outcomes than individuals who undergo a placebo ...

TCT 2017 | SENIOR: DES con polímero reabsorbible y tiempo de doble antiagregación corto en pacientes añosos

TCT 2017 | SENIOR: DES with a Bioresorbable Polymer and Short Dual Antiplatelet Therapy in Elderly Patients
 Courtesy of the SBHCI. This study sought to assess the safety and efficacy of an everolimus-eluting stent with a biodegradable polymer (SYNERGY II) vs. a conventional stent ...

TCT 2017 | REDUCE: 3 vs 12 meses de doble antiagregación con el nuevo DES Combo

TCT 2017 | REDUCE: 3 vs 12 Months of Dual Antiplatelet Therapy with the New Combo DES
Courtesy of SBHCI. This new device has, on one hand, an abluminal sirolimus coating, and on the other hand, a luminal CD34 antibody coating for EPC capturing, to potentially accelerate ...

ABSORB III: a 3 años continua la desilusión de la plataforma bioabsorbible

ABSORB III: after 3 Years, the Bioresorbable Scaffold is Still a Disappointment
Courtesy of the SBHCI. The 3-year outcomes of the ABSORB III trial, which randomized 2008 patients 2:1 to an everolimus eluting bioresorbable scaffold  (1322 patients) ...

Absorb IV: la plataforma bioabsorbible con una técnica de implante perfeccionada

Absorb IV: Bioresorbable Scaffolds with an Optimized Implantation Technique
 Courtesy of the SBHCI. The Absorb IV trial randomized 2604 patients in a 1:1 ratio to receive an Absorb everolimus-eluting bioresorbable scaffold or a Xience ...

ABSORB II: sin beneficios de la plataforma luego de su reabsorción completa

ABSORB II: No Benefits from Scaffolds After Complete Bioresorption
 Courtesy of the SBHCI. The ABSORB II study sought to assess the mechanical properties of everolimus-eluting bioresorbable scaffolds , such as the increase in minimal lumen ...

DKCRUSH-V: lo más simple no siempre es lo mejor en el tronco de la coronaria izquierda

DKCRUSH-V: What Is Simple Is Not Always Best for the Left Main Coronary Artery
Courtesy of the SBHCI. Angioplasty of true distal left main bifurcation lesions with a double-kissing (DK) crush two-stent strategy, compared with provisional stenting, results ...

EXCEL-QOL Substudy: similar calidad de vida con cirugía y angioplastia para el tronco

EXCEL-QOL Substudy: Similar Quality of Life both with CABG and Left Main PCI
Courtesy of SBHCI. According to a new quality of life sub-study, the “EXCEL”, both coronary artery bypass graft  and left main PCI   are associated with significant ...

HREVS: la revascularización híbrida no ofrece ventajas en la enfermedad de múltiples vasos

HREVS: Hybrid Revascularization Offers No Advantage in Multivessel Disease
Courtesy of SBHCI. Hybrid revascularization , which combines CABG with PCI, failed to reduce myocardial ischemia and major cardiac and cerebrovascular events, compared to  ...

CULPRIT-SHOCK Results Will Transform Guidelines and Clinical Practice
 Courtesy of the SBHCI. After treating the culprit lesion in patients with acute myocardial infarction complicated by cardiogenic shock, continuing revascularization of all ...

DARE: los balones farmacológicos compiten con los DES para tratar la reestenosis intrastent

DARE: Drug-Coated Balloons Compete with DES for the Treatment of In-Stent Restenosis
Courtesy of the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI). The SeQuent Please paclitaxel -coated balloon provides non-inferior angiographic results when ...

TCT 2017 | SENIOR: DES con polímero reabsorbible y tiempo de doble antiagregación corto en pacientes añosos

TCT 2017 | SENIOR: DES with a Bioresorbable Polymer and Short Dual Antiplatelet Therapy in Elderly Patients
 Courtesy of the SBHCI. This study sought to assess the safety and efficacy of an everolimus-eluting stent with a biodegradable polymer (SYNERGY II) vs. a conventional stent ...

TCT 2017 | REDUCE: 3 vs 12 meses de doble antiagregación con el nuevo DES Combo

TCT 2017 | REDUCE: 3 vs 12 Months of Dual Antiplatelet Therapy with the New Combo DES
Courtesy of SBHCI. This new device has, on one hand, an abluminal sirolimus coating, and on the other hand, a luminal CD34 antibody coating for EPC capturing, to potentially accelerate ...

Top